Guardant Health announced that its Shield blood test for colorectal cancer screening is now covered for eligible UnitedHealth Group members aged 45 and over, extending access to roughly 40 million people in employer, individual and Medicare-related plans. The move highlights UnitedHealth Group's role in broadening access to newer cancer screening technologies, potentially reshaping how its members manage preventive care and early detection. UnitedHealth Group reaffirmed its 2025 full year guidance of more than US$439,000 million in revenue and over US$24,000 million in operating earnings, providing a reference point for how such additions might be absorbed within its large cost and revenue base.
Guardant Health IncGuardant's Shield blood test coverage expanded to UnitedHealth members aged 45+, increasing potential test volume.
UnitedHealth Group IncorporatedUnitedHealth is mentioned as expanding coverage but reaffirmed guidance; no material financial impact indicated.